Ligand is a high-growth company with economic rights to some of the world's most important medicines.
Ligand’s portfolio covers a diverse array of therapeutic areas, partners and underlying technologies with many products in late stage development.
Ligand’s investment in new technology has resulted in cutting-edge innovations that are making major drugs possible.
Ligand has multiple technologies and unpartnered programs available for out-licensing.
Feb 21, 2018 • 4:01 PM EST
Ligand Reports Fourth Quarter and Full Year 2017 Financial Results
Feb 5, 2018 • 4:01 PM EST
Ligand to Report Fourth Quarter and Full Year 2017 Results on February 21st
Jan 22, 2018 • 9:00 AM EST
Ligand Enters into Worldwide OmniAb® Platform License Agreement with Ferring Pharmaceuticals
Feb 21, 2018 • 4:30pm EST
See all events
Nov 14, 2017 • 4:00pm EST
New York, NY
Nov 7, 2017 • 1:00pm EST
$MLNT partner Eurofarma Laboratórios submits marketing authorization application for delafloxacin (marketed as Baxd… https://t.co/FntVNvgpoX
OmniAb partner Ferring Pharmaceuticals (@Ferring) announces investment in new antibody-focused biotech center in Sw… https://t.co/kIF1qqmF50
$MEIP announces interim data review of clinical trial of ME-344 in patients with HER2-negative breast cancer suppor… https://t.co/Ee7ucOMx5i